CN117222626A - 取代三嗪化合物 - Google Patents
取代三嗪化合物 Download PDFInfo
- Publication number
- CN117222626A CN117222626A CN202280031504.2A CN202280031504A CN117222626A CN 117222626 A CN117222626 A CN 117222626A CN 202280031504 A CN202280031504 A CN 202280031504A CN 117222626 A CN117222626 A CN 117222626A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- alkylene
- substituted
- group
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-075905 | 2021-04-28 | ||
| JP2021075905 | 2021-04-28 | ||
| PCT/JP2022/018994 WO2022230912A1 (ja) | 2021-04-28 | 2022-04-27 | 置換トリアジン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117222626A true CN117222626A (zh) | 2023-12-12 |
Family
ID=83848494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280031504.2A Pending CN117222626A (zh) | 2021-04-28 | 2022-04-27 | 取代三嗪化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240239758A1 (https=) |
| EP (1) | EP4345097A4 (https=) |
| JP (1) | JPWO2022230912A1 (https=) |
| KR (1) | KR20240004371A (https=) |
| CN (1) | CN117222626A (https=) |
| AU (1) | AU2022267160A1 (https=) |
| BR (1) | BR112023022451A2 (https=) |
| CA (1) | CA3218212A1 (https=) |
| MX (1) | MX2023012795A (https=) |
| TW (1) | TW202309000A (https=) |
| WO (1) | WO2022230912A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118440041A (zh) * | 2024-07-02 | 2024-08-06 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| KR20240019083A (ko) | 2021-06-04 | 2024-02-14 | 에프. 호프만-라 로슈 아게 | 트리아진 유도체 및 암 치료에서 이의 용도 |
| HRP20251513T1 (hr) | 2021-07-02 | 2026-01-02 | Astrazeneca Ab | Inhibitori inflamasoma nlrp3 |
| CN116102535A (zh) * | 2021-10-22 | 2023-05-12 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| IL314025A (en) * | 2022-01-07 | 2024-08-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024094150A1 (en) * | 2022-11-04 | 2024-05-10 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| WO2024094185A1 (zh) * | 2022-11-04 | 2024-05-10 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| WO2024157953A1 (ja) * | 2023-01-24 | 2024-08-02 | 第一三共株式会社 | 置換ベンゼン化合物 |
| CN120435466A (zh) * | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
| KR20250158072A (ko) * | 2023-03-20 | 2025-11-05 | 인실리코 메디신 아이피 리미티드 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| WO2024193699A1 (zh) * | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025059069A1 (en) * | 2023-09-12 | 2025-03-20 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| KR102925387B1 (ko) | 2019-02-04 | 2026-02-10 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| AR121669A1 (es) | 2020-03-27 | 2022-06-29 | Astellas Pharma Inc | Compuesto de piridazina sustituida |
| KR20240019083A (ko) * | 2021-06-04 | 2024-02-14 | 에프. 호프만-라 로슈 아게 | 트리아진 유도체 및 암 치료에서 이의 용도 |
| CN116102535A (zh) * | 2021-10-22 | 2023-05-12 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
-
2022
- 2022-04-27 US US18/288,588 patent/US20240239758A1/en active Pending
- 2022-04-27 BR BR112023022451A patent/BR112023022451A2/pt unknown
- 2022-04-27 CA CA3218212A patent/CA3218212A1/en active Pending
- 2022-04-27 KR KR1020237036874A patent/KR20240004371A/ko active Pending
- 2022-04-27 EP EP22795825.3A patent/EP4345097A4/en active Pending
- 2022-04-27 WO PCT/JP2022/018994 patent/WO2022230912A1/ja not_active Ceased
- 2022-04-27 CN CN202280031504.2A patent/CN117222626A/zh active Pending
- 2022-04-27 TW TW111116038A patent/TW202309000A/zh unknown
- 2022-04-27 AU AU2022267160A patent/AU2022267160A1/en active Pending
- 2022-04-27 MX MX2023012795A patent/MX2023012795A/es unknown
- 2022-04-27 JP JP2023517579A patent/JPWO2022230912A1/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118440041A (zh) * | 2024-07-02 | 2024-08-06 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022230912A1 (https=) | 2022-11-03 |
| US20240239758A1 (en) | 2024-07-18 |
| AU2022267160A1 (en) | 2023-11-23 |
| TW202309000A (zh) | 2023-03-01 |
| BR112023022451A2 (pt) | 2024-01-02 |
| MX2023012795A (es) | 2023-11-08 |
| KR20240004371A (ko) | 2024-01-11 |
| WO2022230912A1 (ja) | 2022-11-03 |
| CA3218212A1 (en) | 2022-11-03 |
| EP4345097A4 (en) | 2025-04-23 |
| EP4345097A1 (en) | 2024-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117222626A (zh) | 取代三嗪化合物 | |
| EP3728238B1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| TWI802591B (zh) | 具有環狀構造的化合物 | |
| JP2019532945A (ja) | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換複素環 | |
| UA129887C2 (uk) | Піперидинові модулятори рецепторів cxcr7 | |
| CN120152974A (zh) | 缩环哒嗪衍生物 | |
| CN107108599A (zh) | 作为Rorγt调节剂的三氟甲基醇 | |
| TW202110831A (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
| JP2023550902A (ja) | 新規インダゾールアセチレン誘導体 | |
| CN113045569B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| CN108137608A (zh) | Janus激酶1选择性抑制剂及其药物用途 | |
| CN114981270A (zh) | Mll1抑制剂和抗癌剂 | |
| US20240425523A1 (en) | Compounds for the Degradation of EGFR Kinase | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
| HK40039990A (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| HK40039990B (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| US20250346592A1 (en) | Heterocyclic pad4 inhibitors | |
| HK40041233A (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| HK40056402A (en) | Quinazoline compound and pharmaceutical application thereof | |
| HK40006016B (en) | Piperidines as menin inhibitors | |
| HK40006016A (en) | Piperidines as menin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240206 Address after: Tokyo Applicant after: ASTELLAS PHARMA Inc. Country or region after: Japan Address before: Tokyo Applicant before: ASTELLAS PHARMA Inc. Country or region before: Japan Applicant before: KOTOBUKI PHARMACEUTICAL CO.,LTD. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250409 Address after: Illinois Applicant after: Nico Therapy Co.,Ltd. Country or region after: U.S.A. Address before: Tokyo, Japan Applicant before: ASTELLAS PHARMA Inc. Country or region before: Japan |